. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Nat Rev Rheumatol. 2011 Nov 1;7(12):708–717. doi: 10.1038/nrrheum.2011.157

Table 1.

Summary of validation studies of diagnostic testing for agonistic antibodies to PDGFR in SSc and serum procalcitonin in infection

Study	Number of cases	Sensitivity	Specificity	Controlled for				Disease controls included?	Accepted classification criteria used?	Studied patients with both early and late disease?	Included patients with active and inactive disease?
Study	Number of cases	Sensitivity	Specificity	Age	Gender	Race	Treatment	Disease controls included?	Accepted classification criteria used?	Studied patients with both early and late disease?	Included patients with active and inactive disease?
*Agonistic anti-PDGFR antibodies in SSc*
Baroni et al. (2006)⁷	46	1.00	1.00	Yes	Yes	Yes	Yes, (Patients were all treatment naive)	Yes	Yes	Yes (more patients with early than late disease were included)	Yes
Classen et al. (2009)¹⁰	37	ND	ND	No	No	No	No	Yes	Yes	No	No
Loizos et al. (2009)¹¹	49	ND	ND	No	No	No	No	No	Yes	No	No
*Serum procalcitonin in infection*
Tamaki et al. (2008)²⁴	29	0.53	0.97	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes
Scirè et al. (2006)²⁵	19	0.73	0.89	No	No	No	Yes	Yes	Yes	NA	Yes

Abbreviations: NA, not applicable; ND, not detected; PDGFR, platelet-derived growth factor receptor; SSc, systemic sclerosis.